Catabasis Pharmaceuticals (CATB)

[RealGenius]

Presenting data
Joanne Donovan, M.D., Ph.D., chief medical officer of Catabasis, will present a poster titled “CAT-1004, an oral agent targeting NF-kB in development for treatment of Duchenne muscular dystrophy: Phase 1 / 2 study design.” The poster presentation will take place in the Drug Therapies for DMD session on Friday, October 2, 2015, from 3:00pm – 4:30pm local time in the Brighton Dome.